










# CHECKLIST FOR NPLATE® SELF-ADMINISTRATION

## Confirm that your patient is...

<b>An adult patient</b>	
<b>Interested in and suitable for home administration</b>	
<b>On a stable dose of Nplate®</b> <ul style="list-style-type: none"><li>For the purposes of self-administration, a stable dose of Nplate® means the patient's Nplate® dose has not required adjustment for at least 4 weeks. Patients who need dose adjustments cannot return to self-administration until their dose has stabilised – that is, until their Nplate® dose has not required adjustment for at least 4 weeks</li></ul>	
<b>Willing to undergo a period of training</b> <ul style="list-style-type: none"><li>Inform patients that home administration will involve a period of training, and that they will be required to demonstrate their ability to self-administer</li></ul>	

## Ensure patients return home with...

<b>The right dose written and drawn in their <i>Self-administration diary</i></b>	
<b>Their reconstitution pack(s) of Nplate®</b> (Make sure they have not taken the placebo demonstration kit with them by mistake)	
<b>All the patient materials in their <i>Home Administration Training pack</i></b>	
<b>Contact information for a healthcare professional (to be written on the back of their <i>Self-administration diary</i>, in the section titled "Just in case you need support...")</b>	
<b>An appointment date to return after the first 4 weeks of self-administration. At this visit they will have their platelet count checked and will again be supervised while reconstituting and administering Nplate®. Only patients who demonstrate the ability to reconstitute and self-administer Nplate® should be allowed to continue doing so</b>	

Adverse reactions/events should be reported to the Health Products  
Regulatory Authority (HPRA) using the available methods via  
[www.hpra.ie](http://www.hpra.ie).

Adverse events should also be reported to Amgen Limited on  
+44 (0) 1223 436441.